Charles Schwab
FBLG icon

Charles Schwab’s FibroBiologics FBLG Stock Holding History

Charles Schwab’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,490
Closed -$62.8K – 3592
2025
Q1 		$62.8K Buy
3,490
+3
+0.1% +$86 ﹤0.01% 3384
2024
Q4 		$139K Hold
3,487
– – ﹤0.01% 3369
2024
Q3 		$215K Buy
3,487
+173
+5% +$11.5K ﹤0.01% 3325
2024
Q2 		$331K Buy
+3,314
New +$632K ﹤0.01% 3339

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's FBLG Position: Q2 2025 in Review

Charles Schwab sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 3,490 shares — an estimated $62.8K sold.

Charles Schwab first reported a position in FBLG in Q2 2024 and held it in 4 quarters. The position peaked at $331K in Q2 2024. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

  • Charles Schwab reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 3,490 FibroBiologics shares in Q2 2025, an estimated $62.8K.
  • Charles Schwab first reported a position in FibroBiologics in Q2 2024 and held it in 4 quarters.
  • Charles Schwab's FibroBiologics position peaked at $331K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.